Documentos de Académico
Documentos de Profesional
Documentos de Cultura
LEVOFLOXACINO
MOXIFLOXACINO
Optimal Management of Neutropenic Fever in Patients with Cáncer
Andrea J. Zimmer, MD1 and Alison G. Freifeld, MD1
PROFILAXIS CON FLUOROQUINOLONAS
EN NEUTROPENIA.
FEBRIL
ANC
ANC 500-
MENOR
1000/mm3
500/mm3
Det
e
inm rioro
inen
te
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
ANTIBIOTICOS EMPIRICO DE ELECCION CUANDO
NO EXISTE FOCO EVIDENTE DE INFECCION.
BETALACTAMICO • MONOTERAPIA
CON ACTIVIDAD • COMBINADO, SEGÚN MULTIRESISTENCIA
PSEUDOMONA
• NO CEFALOSPORINAS, PIP/TAZO EN
PREVALENCIA ESB MONOTERAPIA.
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
RECOMIENDA. INESTABLE
S
MONOTERAPIA VANCO,DAPTO,LINEZOLI
S
MEROPENEM O D
ICO
IMIPENEM
IT
CR
CONSIDERAR
ANTIFUNGICOS
BETALACTAMICO
ANTIPSEUDOMONA
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
DURACIÓN DE TRATAMIENTO SIN INFECCION
DOCUMENTADA CLINICA O MICROBIOLOGICA
INDEPENDIENTE DEL
RECUENTO DE NEUTROFILOS
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
ANTIBIOTICOS EMPIRICOS CUANDO EXISTE
UNA FUENTE CLINICA DE INFECCION.
MUCOSITIS/
ENTEROCOLITIS
ESOFAGITIS
AMPLIO ESPECTRO
LEVE: CEFEPIME, GRAM +
NO ANAEROBIOS GRAM –
ANAEROBIOS
SEVERA:
ANAEROBICOS, PIP/TAZO,
PIP/TAZO, IMIPENEM,
IMIPENEM, MEROPENEM
MEROPENEM
C. Dificile
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
• CONTRAINDICADO TACTO RECTAL
• PIP/TAZO, IMIPENEM, MEROPENEM
INFECCION
PERIANAL
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
SENOS
PARANASALE NEUMONIA
S
NEUTROPENIA
PROLONGADA, NEUMONIA ATIPICA
COBERTURA ASPERGILLUS
CORTICOIDE. MACROLIDO/FLUOROQUINOLONA
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
• BETALACTAMICO CON ACTIVIDAD
PSEUDOMONA
INFECCION TRACTO URINARIO • EN PACIENTES CRITICOS AGREGAR SEGUNDO
ANTIBIOTICO (AMINOGLUCOSIDO)
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
DURACIÓN DE TRATAMIENTO CON AISLAMIENTO
MICROBIOLOGICO DOCUMENTADO
CURACION CLINICA,
MICROBIOLOGICA SI LA NEUTROPENIA PERSISTE
DESPUES DE SUSPENDER EL
TRATAMIENTO
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
TRATAMIENTO DE INFECCIONES POR
MDR
BLEE
• CARBAPENEMICOS INFUSION PROLONGADA
• EVITAR PIP/TAZO MIC MAS 4MG/L
AMPC
• CEFEPIME/FLUOROQUINOLONA
• EVITAR PIP/TAZO MIC MAS 4MG/L
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
TRATAMIENTO DE INFECCIONES POR
CRE
COMBINACION ATB
MERO,
COLISTIN,TIGECI,FOSFO
,AMINOGLUCOSIDOS
CEFTAZIDIMA/
AVIBACTAM
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
TERAPIA PARA STENOTROPHONOMA
COTRIMOXAZOL
(TRIMETOPRIM 15MG/KG 3-4
TOMAS)
ALTERNATIVA:
MINOCICLINA/FLUOROQUINOLONA
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
NEUTROPENIA FEBRIL CON
RECUPERACION NEUTROFILOS
EN PACIENTES CON INFECCIÓN DOCUMENTADA LA DURACIÓN DEL
TRATAMIENTO SE BASA EN EL ORGANISMO AISLADO Y EL SITIO DE
INFECCIÓN, CONTINUAR HASTA LA RECUPERACIÓN DE LA NEUTROPENIA
(CN≥500CÉLULAS/MM3).
Neutropenia febril: el punto de vista del hematólogo Febrile neutropenia: From the haematologist point of view
José Ramón Rivas Llamas
Agrupación Mexicana para el Estudio de la Hematología AC, Culiacán, Sinaloa, México
INDICACION DE FACTOR ESTIMULANTE
DE COLONIAS DE GRANULOCITOS
MAYOR RIESGO DE COMPLICACIONES RELACIONADO CON MAL
PRONOSTICO.
NO SE RECOMIENDA PROFILAXIS EN BAJO RIESGO
PROFILAXIS PRIMARIA PARA LOS PACIENTE QUE PRESENTARON
NEUTROPENIA EN UN CICLO ANTERIOR DE QT O CUYO
RIESGO DE NF ES MAS DEL 20%.
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish
Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with
hematological malignancies.
MEDIDAS DE CONTROL